BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 28634007)

  • 21. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
    Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
    Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic clonal mapping of in situ and invasive ductal carcinoma indicates the field cancerization phenomenon in the breast.
    Foschini MP; Morandi L; Leonardi E; Flamminio F; Ishikawa Y; Masetti R; Eusebi V
    Hum Pathol; 2013 Jul; 44(7):1310-9. PubMed ID: 23337025
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene amplification in ductal carcinoma in situ of the breast.
    Burkhardt L; Grob TJ; Hermann I; Burandt E; Choschzick M; Jänicke F; Müller V; Bokemeyer C; Simon R; Sauter G; Wilczak W; Lebeau A
    Breast Cancer Res Treat; 2010 Oct; 123(3):757-65. PubMed ID: 20033484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS.
    Visser LL; Elshof LE; Van de Vijver K; Groen EJ; Almekinders MM; Sanders J; Bierman C; Peters D; Hofland I; Broeks A; van Leeuwen FE; Rutgers EJT; Schmidt MK; Schaapveld M; Lips EH; Wesseling J
    Am J Surg Pathol; 2019 Nov; 43(11):1574-1582. PubMed ID: 31206365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extensive DCIS component.
    Liao N; Zhang GC; Liu YH; Li XR; Yao M; Xu FP; Li L; Wu YL
    Pathol Res Pract; 2011 Jan; 207(1):1-7. PubMed ID: 21095069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Classification of ductal carcinoma in situ by gene expression profiling.
    Hannemann J; Velds A; Halfwerk JB; Kreike B; Peterse JL; van de Vijver MJ
    Breast Cancer Res; 2006; 8(5):R61. PubMed ID: 17069663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
    Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
    Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection.
    Hernandez L; Wilkerson PM; Lambros MB; Campion-Flora A; Rodrigues DN; Gauthier A; Cabral C; Pawar V; Mackay A; A'Hern R; Marchiò C; Palacios J; Natrajan R; Weigelt B; Reis-Filho JS
    J Pathol; 2012 May; 227(1):42-52. PubMed ID: 22252965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic differences between pure ductal carcinoma in situ of the breast and that associated with invasive disease: a calibrated aCGH study.
    Iakovlev VV; Arneson NC; Wong V; Wang C; Leung S; Iakovleva G; Warren K; Pintilie M; Done SJ
    Clin Cancer Res; 2008 Jul; 14(14):4446-54. PubMed ID: 18628458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component.
    Yu KD; Wu LM; Liu GY; Wu J; Di GH; Shen ZZ; Shao ZM
    Ann Surg Oncol; 2011 May; 18(5):1342-8. PubMed ID: 21042943
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
    Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
    Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ.
    Sharma M; Beck AH; Webster JA; Espinosa I; Montgomery K; Varma S; van de Rijn M; Jensen KC; West RB
    Breast Cancer Res Treat; 2010 Sep; 123(2):397-404. PubMed ID: 19949854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer.
    Choi Y; Lee HJ; Jang MH; Gwak JM; Lee KS; Kim EJ; Kim HJ; Lee HE; Park SY
    Hum Pathol; 2013 Nov; 44(11):2581-9. PubMed ID: 24055090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ectopic expression of PLC-β2 in non-invasive breast tumor cells plays a protective role against malignant progression and is correlated with the deregulation of miR-146a.
    Bertagnolo V; Grassilli S; Volinia S; Al-Qassab Y; Brugnoli F; Vezzali F; Lambertini E; Palomba M; Piubello Q; Orvieto E; Natali C; Piva R; Croce CM; Capitani S
    Mol Carcinog; 2019 May; 58(5):708-721. PubMed ID: 30582225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Detection and clinical significance of Notch1 methylation in breast cancer and intraductal proliferative breast lesions].
    Zhang N; Sun ZZ; Li F; Cao YW; Zhao CX; Liang WH; Sun HP; Li HA; Fu XG
    Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):324-9. PubMed ID: 21756827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S; Wang J; Bourne P; Yang Q; Tang P
    Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Loss of FAT1 during the progression from DCIS to IDC and predict poor clinical outcome in breast cancer.
    Wang L; Lyu S; Wang S; Shen H; Niu F; Liu X; Liu J; Niu Y
    Exp Mol Pathol; 2016 Feb; 100(1):177-83. PubMed ID: 26721716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene expression profiling of ductal carcinomas in situ and invasive breast tumors.
    Seth A; Kitching R; Landberg G; Xu J; Zubovits J; Burger AM
    Anticancer Res; 2003; 23(3A):2043-51. PubMed ID: 12894577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Whole-Exome Sequencing Analysis of the Progression from Non-Low-Grade Ductal Carcinoma
    Pareja F; Brown DN; Lee JY; Da Cruz Paula A; Selenica P; Bi R; Geyer FC; Gazzo A; da Silva EM; Vahdatinia M; Stylianou AA; Ferrando L; Wen HY; Hicks JB; Weigelt B; Reis-Filho JS
    Clin Cancer Res; 2020 Jul; 26(14):3682-3693. PubMed ID: 32220886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.